Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Item
http://www.wikidata.org/entity/Q34341465
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsIntravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.New drug targets in metastatic melanoma."RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer.Advanced molecular dynamics simulation methods for kinase drug discovery.Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape.Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?Neurological update: gliomas and other primary brain tumours in adults.Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation.Malignant Melanoma.GDA, a web-based tool for Genomics and Drugs integrated analysis.HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosisIs time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
P2860

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Item
http://www.wikidata.org/entity/Q34341465
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@ast
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@en
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@nl
type
label
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@ast
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@en
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@nl
prefLabel
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@ast
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@en
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@en
P2093
P2860
P304
P31
P356
10.1517/17425255.2013.794220
P407
P433
P478
P577
P698
P921